respiratori
tract
infect
rti
among
common
infecti
diseas
human
worldwid
caus
signific
morbid
mortal
consequ
respons
enorm
econom
burden
societi
term
visit
doctor
treatment
hospitalis
absenc
work
school
upper
respiratori
viral
infect
frequent
approxim
infect
per
year
children
infect
per
year
adult
actual
cost
upper
rti
urti
difficult
determin
includ
factor
overprescript
antibiot
absenc
work
lower
rti
lrti
less
frequent
upper
rti
urti
patient
lrti
hospitalis
cost
infect
higher
exampl
econom
cost
viral
lrti
children
estim
billion
us
dollar
annual
henrickson
clinic
diagnosi
usual
discrimin
caus
agent
therefor
initi
treatment
empir
known
urti
like
viral
lower
respiratori
tract
commonli
detect
bacteri
viral
caus
infect
distinguish
clinic
examin
requir
diagnost
test
earli
diagnosi
aetiolog
agent
enabl
effect
antimicrobi
therapi
appropri
manag
infect
nucleic
acid
amplif
methodolog
revolutionis
diagnosi
infecti
diseas
provid
time
accur
depend
diagnosi
enabl
initi
appropri
intervent
without
delay
improv
patient
care
ultim
reduc
cost
great
strength
molecular
techniqu
especi
multiplex
test
increas
sensit
creat
mean
test
numer
pathogen
use
common
system
mani
pathogen
previous
unabl
detect
techniqu
dfa
cultur
clinic
impact
rapid
diagnosi
mainli
assess
use
nonmolecular
rapid
test
one
prospect
studi
impact
time
diagnosi
influenza
examin
patient
age
month
year
one
group
knew
diagnosi
patient
unblind
group
signific
decreas
antibiot
use
number
test
perform
lower
associ
charg
reduc
length
stay
emerg
depart
bonner
et
al
far
cost
benefit
analys
pcr
limit
expect
appear
molecular
assay
implement
understand
clinic
cours
consequ
infect
extrem
valuabl
exampl
consid
child
attend
accid
emerg
e
bronchiol
two
pathogen
identifi
respiratori
syncyti
viru
rsv
rhinoviru
rv
rapid
detect
multipl
respiratori
virus
possibl
molecular
method
infant
infect
rsv
first
year
life
children
infect
least
age
two
initi
rsv
infect
typic
sever
caus
lrt
diseas
bronchioloti
infant
recent
preval
rv
infect
bronchiol
underestim
clear
rv
infect
lrt
molecular
techniqu
viral
diagnosi
increas
evid
rv
contributor
bronchiol
probabl
fairli
common
jacqu
et
al
coinfect
rsv
also
lead
sever
ill
manner
manag
child
would
guid
diagnosi
beyond
support
care
also
suggest
rv
compar
rsv
may
respons
antiinflammatori
therapi
infect
rv
rsv
treat
system
corticosteroid
reduc
recurr
wheez
situat
viral
diagnosi
help
understand
prognosi
infect
lead
hospitalis
prolong
hospit
stay
eg
pneumonia
sever
lrti
increasingli
recognis
virus
signific
part
mixtur
pathogen
found
pneumonia
exampl
patient
itu
commun
acquir
pneumonia
cap
may
haemophilu
influenza
isol
also
parainfluenza
viru
type
detect
templeton
et
al
detect
multipl
pathogen
may
suggest
pneumonia
sever
patient
may
requir
longer
stay
itu
influenza
patient
cap
complic
secondari
bacteri
pneumonia
although
antibiot
treatment
part
treatment
viral
infect
may
start
owe
likelihood
secondari
bacteri
pneumonia
secondari
bacteri
pneumonia
import
caus
influenzaassoci
death
although
bacteri
therapi
standard
antivir
therapi
ignor
viral
infect
usual
resolv
time
bacteri
pneumonia
present
scad
report
death
seri
patient
secondari
bacteri
pneumonia
case
fatal
rate
scad
paper
modern
era
report
mortal
nicholson
thu
overal
likelihood
death
pneumonia
patient
influenza
secondari
bacteri
pneumonia
high
affect
antimicrobi
efficaci
studi
mice
shown
mcculler
treatment
predispos
influenza
viru
infect
inhibitor
specif
viral
neuraminidas
might
improv
efficaci
antibiot
increas
surviv
person
high
risk
complic
mortal
influenza
mcculler
clear
rapid
accur
diagnosi
central
therapi
decis
molecular
method
compar
dfa
sensit
screen
requir
within
hour
admiss
hospit
advantag
heighten
sensit
difficult
specimen
sputum
anoth
area
diagnosi
role
play
immunocompromis
patient
screen
patient
prior
stem
cell
transplant
perform
part
patient
manag
respiratori
viru
detect
prior
condit
decis
whether
transplant
delay
viru
clear
must
consid
brediu
et
al
studi
paediatr
haematopoiet
stem
cell
transplant
patient
screen
use
pcr
test
respiratori
virus
whether
patient
symptomat
symptomat
asymptomat
patient
viral
infect
detect
use
molecular
assay
screen
tool
exclud
respiratori
virus
also
import
part
diagnosi
manag
patient
mani
respiratori
virus
best
detect
molecular
techniqu
neither
cultur
dfa
effici
particular
relev
immunocompromis
patient
especi
adult
shown
signific
rate
infect
human
metapneumoviru
hmpv
martino
et
al
best
diagnos
use
molecular
techniqu
equal
import
make
correct
diagnosi
immunocompromis
patient
present
respiratori
infect
febril
neutropenia
respiratori
viral
infect
easili
transmit
close
environ
copiou
amount
respiratori
secret
increas
chanc
infect
spread
children
often
produc
greatest
volum
knowledg
viru
virus
isar
present
close
contact
may
guid
use
antivir
agent
prophylaxi
vaccin
child
chronic
cardiac
diseas
increas
risk
catch
rsv
palivizumab
administ
prevent
sever
complic
rsv
infect
equal
parainfluenza
viru
detect
patient
admit
haematolog
ward
patient
isol
prevent
viral
infect
ward
outbreak
rsv
neonat
intens
care
unit
nicu
led
nine
infant
infect
situat
brought
control
spread
stop
outbreak
cost
hospit
million
us
dollar
cost
attend
physician
felt
could
significantli
reduc
rsv
diagnos
soon
symptom
began
develop
facil
recommend
infant
nicu
develop
cough
congest
apnoea
test
rsv
common
respiratori
virus
winter
season
halasa
et
al
paediatr
itu
edinburgh
patient
screen
twice
weekli
respiratori
virus
regardless
symptom
part
infect
control
measur
demonstr
pcr
posit
day
symptom
present
immunocompomuis
patient
obviou
manag
implic
cost
associ
outbreak
paediatr
itu
nosocomi
case
estim
serwint
miller
outbreak
sar
increas
report
sever
avian
influenza
exampl
justifi
respiratori
viral
test
mean
prevent
transmiss
rapid
diagnosi
detect
presenc
sar
cov
avian
influenza
would
enabl
appropri
measur
taken
sinc
infect
pose
extrem
challeng
manag
hospit
detect
routin
season
virus
allow
altern
diagnosi
made
rapidli
clinic
case
relat
sar
virus
indistinguish
louie
et
al
investig
common
pneumonia
patient
suspect
sar
diagnos
normal
season
virus
suspect
sar
case
sar
could
exclud
patient
molecular
method
pcr
employ
studi
louie
et
al
earli
diagnosi
influenza
improv
effici
prophylaxi
treatment
antivir
strong
impact
costeffect
cur
treatment
treatment
influenza
neuraminidas
inhibitor
need
administ
within
hour
contact
diagnosi
requir
rapidli
gonzal
et
al
examin
antibiot
use
respiratori
infect
usa
base
bacteri
preval
rate
otiti
media
sinus
pharyng
bronchiti
upper
respiratori
infect
ideal
antibiot
prescript
rate
estim
million
antibiot
prescript
million
estim
prescrib
infect
unlik
bacteri
aetiolog
thu
overus
antibiot
high
econom
cost
microbiolog
diagnosi
may
signific
impact
decreas
excess
inappropri
use
antibiot
gonzal
et
al
excess
antibiot
use
increasingli
recognis
main
select
pressur
drive
resist
studi
investig
outpati
antibiot
use
countri
europ
shift
old
narrowspectrum
antibiot
new
broadspectrum
antibiot
higher
rate
antibiot
resist
higher
consum
countri
goossen
et
al
one
consequ
overprescrib
antibiot
especi
individu
viral
infect
clinic
improv
observ
potenti
risk
caus
antibiot
resist
increas
new
antivir
option
becom
avail
better
treatment
choic
benefit
patient
commun
molecular
techniqu
provid
time
inform
regard
identif
pathogen
detect
guid
clinician
choic
therapi
molecular
diagnost
play
central
role
surveil
respons
epidem
pandem
influenza
circul
highli
pathogen
strain
realtim
assay
use
diagnosi
surveil
purpos
human
anim
microarray
use
identifi
monitor
spread
danger
variant
mani
countri
centr
commun
submit
sampl
laboratori
gain
inform
influenza
viral
subtyp
circul
patient
diagnosi
inform
guid
futur
vaccin
polici
conclus
molecular
diagnosi
respiratori
virus
deliv
time
sensit
result
detect
new
exist
viral
infect
help
understand
role
pathogen
play
particular
infect
guid
manag
regard
treatment
nosocomi
transmiss
enabl
surveil
vaccin
strategi
optim
none
declar
